NASDAQ · CLNNW
Healthcare · Biotechnology
$0.00
Down-$0.00 (-28.00%)
Updated Sep 18, 2026, 4:13 PM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
CLNNW does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning CLNNW.
CLNNW research
Company profile and research snapshot.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
GlobeNewswire Inc. · Dec 2, 2025
Clene Inc. will host an investor call and webcast on December 3, 2025, to provide an update on its CNM-Au8 program for treating amyotrophic lateral sclerosis (ALS). The company is a late clinical-stage biopharmaceutical firm focused on neurodegenerative disease treatments.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CLNNW.
No results
No recent SID articles mention CLNNW.
